Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

No Delays Expected As Australian Bill On Faster Drug Approvals Goes To Parliament

Executive Summary

The Australian parliament has held its first reading of a bill that will implement a number of new measures in the pharmaceutical area, including two new expedited drug approval pathways and a risk-based approach to variations.

You may also be interested in...



Black Triangle Scheme And Formal Inspections On the Cards In Australia

New pharmacovigilance-enhancing proposals from Australia’s Therapeutic Goods Administration signal the agency’s intention to become more proactive when it comes to monitoring drug sponsors.

Australian Provisional Approval Pathway To Get Tough On Sponsors Upfront

Plans by Australia’s Therapeutic Goods Administration to develop a provision approval pathway for drugs have moved up a gear.

Australia Steps Up Priority Review And Faster Assessment Plans

The Therapeutic Goods Administration is seeking feedback on proposals for a priority-review pathway and a system for designating Australian conformity assessment bodies. Both efforts promise to speed products to market and might also involve new fees for industry.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS119611

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel